{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T22:18:06Z","timestamp":1770502686033,"version":"3.49.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.3816\/clm.2006.n.033","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:10:17Z","timestamp":1221095417000},"page":"496-499","source":"Crossref","is-referenced-by-count":23,"title":["Activity of Rituximab Monotherapy in Refractory Splenic Marginal Zone Lymphoma Complicated with Autoimmune Hemolytic Anemia"],"prefix":"10.3816","volume":"6","author":[{"given":"Alberto","family":"Fabbri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Gozzetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Lazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariapia","family":"Lenoci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"D'Amuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Leoncini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Lauria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2006.n.033_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2003.50025","article-title":"The mechanism of action of rituximab in the elimination of tumor cells","volume":"30","author":"Johnson","year":"2003","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2006.n.033_bib2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1191\/0961203305lu2138oa","article-title":"Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases","volume":"14","author":"Chasemberg","year":"2005","journal-title":"Lupus"},{"key":"10.3816\/CLM.2006.n.033_bib3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.autrev.2005.03.002","article-title":"B cell depletion in autoimmune rheumatic diseases","volume":"4","author":"Pitashny","year":"2005","journal-title":"Autoimmunity Rev"},{"key":"10.3816\/CLM.2006.n.033_bib4","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1080\/1042819031000123555","article-title":"Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase","volume":"44","author":"Paydas","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2006.n.033_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/sj.thj.6200329","article-title":"Refractory cold agglutinin-immunohaemolytic anemia associated to marginal zone lymphoma responding to rituximab","volume":"4","author":"Petit","year":"2003","journal-title":"Hematol J"},{"key":"10.3816\/CLM.2006.n.033_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CLM.2002.n.010","article-title":"Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients","volume":"3","author":"Thieblemont","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.3816\/CLM.2006.n.033_bib7","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3816\/CLM.2004.n.005","article-title":"Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma","volume":"4","author":"Arcaini","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.3816\/CLM.2006.n.033_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.blre.2004.03.002","article-title":"Splenic marginal zone lymphoma","volume":"19","author":"Oscier","year":"2005","journal-title":"Blood Rev"},{"key":"10.3816\/CLM.2006.n.033_bib9","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1200\/JCO.2005.05.018","article-title":"State of the art therapeutics: marginal-zone lymphoma","volume":"23","author":"Bertoni","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.033_bib10","first-page":"856","article-title":"Rituximab monotherapy for splenic marginal zone lymphoma","volume":"90","author":"Bennet","year":"2005","journal-title":"Haematol"},{"key":"10.3816\/CLM.2006.n.033_bib11","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombination in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2006.n.033_bib12","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.033_bib13","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single agent rituximab as first line and maintanance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155791901170289X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155791901170289X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T22:59:16Z","timestamp":1545778756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155791901170289X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S155791901170289X"],"URL":"https:\/\/doi.org\/10.3816\/clm.2006.n.033","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}